{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:45:01Z","timestamp":1790790301646,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The alpha-synuclein (aSyn) seed amplification assay (SAA) can identify aSyn aggregates as indicator for Lewy body pathology in biomaterials of living patients and help in diagnosing Parkinson\u00b4s disease and dementia syndromes. Our objective was to confirm that qualitative results of aSyn SAA are reproducible across laboratories and to determine whether quantitative findings correlate with patient clinical characteristics. Therefore cerebrospinal fluid samples were re-analysed by aSyn SAA in a second laboratory with four technical replicates for each sample. Kinetic parameters derived from each aggregation curve were summarized and correlated with patient characteristics. We found that qualitative findings were identical between the two laboratories for 54 of 55 patient samples. The number of positive replicates for each sample also showed good agreement between laboratories. Moreover, specific kinetic parameters of the SAA showed a strong correlation with clinical parameters, notably with cognitive performance evaluated by the Montreal Cognitive Assessment. We concluded that SAA findings are highly reproducible across laboratories following the same protocol. SAA reports not only the presence of Lewy pathology but is also associated with clinical characteristics. Thus, aSyn SAA can potentially be used for patient stratification and determining the target engagement of aSyn targeting treatments.<\/jats:p>","DOI":"10.1186\/s40478-023-01653-3","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T13:03:35Z","timestamp":1696856615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders"],"prefix":"10.1186","volume":"11","author":[{"given":"Stefan","family":"Br\u00e4uer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Sajapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Henle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Parchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-526X","authenticated-orcid":false,"given":"Bj\u00f6rn H.","family":"Falkenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"1653_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30:1591\u20131601","journal-title":"Mov Disord"},{"key":"1653_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/mds.27485","volume":"33","author":"TG Beach","year":"2018","unstructured":"Beach TG, Adler CH (2018) Importance of low diagnostic accuracy for early Parkinson\u2019s disease. Mov Disord 33:1551\u20131554","journal-title":"Mov Disord"},{"key":"1653_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mds.26913","volume":"32","author":"AJ Espay","year":"2017","unstructured":"Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB et al (2017) Biomarker-driven phenotyping in Parkinson\u2019s disease: A translational missing link in disease-modifying clinical trials. Mov Disord 32:319\u2013324","journal-title":"Mov Disord"},{"key":"1653_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nmeth0308-211","volume":"5","author":"R Atarashi","year":"2008","unstructured":"Atarashi R, Wilham JM, Christensen L, Hughson AG, Moore RA, Johnson LM et al (2008) Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat Methods 5:211\u2013212","journal-title":"Nat Methods"},{"key":"1653_CR5","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/mds.28651","volume":"36","author":"A Mammana","year":"2021","unstructured":"Mammana A, Baiardi S, Quadalti C, Rossi M, Donadio V, Capellari S et al (2021) RT-QuIC detection of pathological \u03b1-synuclein in skin punches of patients with Lewy body disease. Mov Disord 36:2173\u20132177","journal-title":"Mov Disord"},{"key":"1653_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/mds.27907","volume":"35","author":"S Manne","year":"2020","unstructured":"Manne S, Kondru N, Jin H, Anantharam V, Huang X, Kanthasamy A et al (2020) \u03b1-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson\u2019s disease patients. Mov Disord 35:268\u2013278","journal-title":"Mov Disord"},{"key":"1653_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40035-019-0164-x","volume":"8","author":"CMG De Luca","year":"2019","unstructured":"De Luca CMG, Elia AE, Portaleone SM, Cazzaniga FA, Rossi M, Bistaffa E et al (2019) Efficient RT-QuIC seeding activity for \u03b1-synuclein in olfactory mucosa samples of patients with Parkinson\u2019s disease and multiple system atrophy. Transl Neurodegener 8:24","journal-title":"Transl Neurodegener"},{"key":"1653_CR8","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S et al (2016) Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 3:812\u2013818","journal-title":"Ann Clin Transl Neurol"},{"key":"1653_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X et al (2020) Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578:273\u2013277","journal-title":"Nature"},{"key":"1653_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman BR, Orr\u00f9 CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B et al (2018) Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC. Acta Neuropathol Commun 6:7","journal-title":"Acta Neuropathol Commun"},{"key":"1653_CR11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno S-I, Imamichi-Tatano Y et al (2023) Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 29:1448\u20131455","journal-title":"Nat Med"},{"key":"1653_CR12","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","volume":"145","author":"A Kluge","year":"2022","unstructured":"Kluge A, Bunk J, Schaeffer E, Drobny A, Xiang W, Knacke H et al (2022) Detection of neuron-derived pathological \u03b1-synuclein in blood. Brain 145:3058\u20133071","journal-title":"Brain"},{"key":"1653_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mds.29246","volume":"38","author":"G Vivacqua","year":"2023","unstructured":"Vivacqua G, Mason M, De Bartolo MI, W\u0119grzynowicz M, Cal\u00f2 L, Belvisi D et al (2023) Salivary \u03b1-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson\u2019s Disease. Mov Disord 38:153\u2013155","journal-title":"Mov Disord"},{"key":"1653_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orr\u00f9 CD et al (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140:49\u201362","journal-title":"Acta Neuropathol"},{"key":"1653_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM et al (2021) High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol Commun 9:179","journal-title":"Acta Neuropathol Commun"},{"key":"1653_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40478-021-01276-6","volume":"9","author":"K Brockmann","year":"2021","unstructured":"Brockmann K, Quadalti C, Lerche S, Rossi M, Wurster I, Baiardi S et al (2021) Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9:175","journal-title":"Acta Neuropathol Commun"},{"key":"1653_CR17","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/ana.26089","volume":"89","author":"W Singer","year":"2021","unstructured":"Singer W, Schmeichel AM, Shahnawaz M, Schmelzer JD, Sletten DM, Gehrking TL et al (2021) Alpha-Synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann Neurol 89:1212\u20131220","journal-title":"Ann Neurol"},{"key":"1653_CR18","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1212\/WNL.0000000000012438","volume":"97","author":"M Rossi","year":"2021","unstructured":"Rossi M, Baiardi S, Teunissen CE, Quadalti C, van de Beek M, Mammana A et al (2021) Diagnostic value of the CSF \u03b1-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies. Neurology 97:e930\u2013e940","journal-title":"Neurology"},{"key":"1653_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/acn3.51280","volume":"8","author":"CD Orr\u00f9","year":"2021","unstructured":"Orr\u00f9 CD, Ma TC, Hughson AG, Groveman BR, Srivastava A, Galasko D et al (2021) A rapid \u03b1-synuclein seed assay of Parkinson\u2019s disease CSF panel shows high diagnostic accuracy. Ann Clin Transl Neurol 8:374\u2013384","journal-title":"Ann Clin Transl Neurol"},{"key":"1653_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I et al (2003) SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 18:467\u2013486","journal-title":"Mov Disord"},{"key":"1653_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89:88\u2013100","journal-title":"Neurology"},{"key":"1653_CR22","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement disorder society-sponsored revision of the unified Parkinson\u2019s Disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results: MDS-UPDRS: clinimetric Assessment. Mov Disord 23:2129\u20132170","journal-title":"Mov Disord"},{"key":"1653_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. J Psychiatr Res 12:189\u2013198","journal-title":"J Psychiatr Res"},{"key":"1653_CR24","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","volume":"73","author":"S Hoops","year":"2009","unstructured":"Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738\u20131745","journal-title":"Neurology"},{"key":"1653_CR25","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.jamda.2022.03.018","volume":"23","author":"M Roheger","year":"2022","unstructured":"Roheger M, Xu H, Hoang MT, Eriksdotter M, Garcia-Ptacek S (2022) Conversion between the mini-mental state examination and the Montreal cognitive assessment for patients with different forms of dementia. J Am Med Dir Assoc 23:1986-1989.e1","journal-title":"J Am Med Dir Assoc"},{"key":"1653_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-020-00603-8","volume":"12","author":"AE Thomann","year":"2020","unstructured":"Thomann AE, Berres M, Goettel N, Steiner LA, Monsch AU (2020) Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment. Alzheimers Res Ther 12:39","journal-title":"Alzheimers Res Ther"},{"key":"1653_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mds.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang UJ, Boehme AK, Fairfoul G, Shahnawaz M, Ma TC, Hutten SJ et al (2019) Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease. Mov Disord 34:536\u2013544","journal-title":"Mov Disord"},{"key":"1653_CR28","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/ene.15387","volume":"29","author":"N McKenzie","year":"2022","unstructured":"McKenzie N, Piconi G, Culeux A, Hammarin A-L, Stergiou C, Tzartos S et al (2022) Concordance of cerebrospinal fluid real-time quaking-induced conversion across the European Creutzfeldt-Jakob Disease Surveillance Network. Eur J Neurol 29:2431\u20132438","journal-title":"Eur J Neurol"},{"key":"1653_CR29","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/acn3.51219","volume":"7","author":"CD Orr\u00fa","year":"2020","unstructured":"Orr\u00fa CD, Groveman BR, Foutz A, Bongianni M, Cardone F, McKenzie N et al (2020) Ring trial of 2nd generation RT-QuIC diagnostic tests for sporadic CJD. Ann Clin Transl Neurol 7:2262\u20132271","journal-title":"Ann Clin Transl Neurol"},{"key":"1653_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3233\/JPD-2011-11046","volume":"1","author":"L Parkkinen","year":"2011","unstructured":"Parkkinen L, O\u2019Sullivan SS, Collins C, Petrie A, Holton JL, Revesz T et al (2011) Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson\u2019s disease. J Parkinsons Dis 1:277\u2013286","journal-title":"J Parkinsons Dis"},{"key":"1653_CR31","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH et al (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain 136:2419\u20132431","journal-title":"Brain"},{"key":"1653_CR32","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00415-019-09348-3","volume":"266","author":"A Regnault","year":"2019","unstructured":"Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S (2019) Does the MDS-UPDRS provide the precision to assess progression in early Parkinson\u2019s disease? Learnings from the Parkinson\u2019s progression marker initiative cohort. J Neurol 266:1927\u20131936","journal-title":"J Neurol"},{"key":"1653_CR33","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/WNL.54.10.1916","volume":"54","author":"HI Hurtig","year":"2000","unstructured":"Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM et al (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson\u2019s disease. Neurology 54:1916\u20131921","journal-title":"Neurology"},{"key":"1653_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s004019900168","volume":"100","author":"PM Mattila","year":"2000","unstructured":"Mattila PM, Rinne JO, Helenius H, Dickson DW, R\u00f6ytt\u00e4 M (2000) Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson\u2019s disease. Acta Neuropathol 100:285\u2013290","journal-title":"Acta Neuropathol"},{"key":"1653_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/mds.27492","volume":"34","author":"B Mollenhauer","year":"2019","unstructured":"Mollenhauer B, Zimmermann J, Sixel-D\u00f6ring F, Focke NK, Wicke T, Ebentheuer J et al (2019) Baseline predictors for progression 4 years after Parkinson\u2019s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Disord 34:67\u201377","journal-title":"Mov Disord"},{"key":"1653_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","volume":"75","author":"A Siderowf","year":"2010","unstructured":"Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A et al (2010) CSF amyloid beta 1\u201342 predicts cognitive decline in Parkinson disease. Neurology 75:1055\u20131061","journal-title":"Neurology"},{"key":"1653_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13195-019-0537-5","volume":"11","author":"I van Steenoven","year":"2019","unstructured":"van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW (2019) Amyloid-\u03b2 peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimers Res Ther 11:83","journal-title":"Alzheimers Res Ther"},{"key":"1653_CR38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00702-016-1517-6","volume":"123","author":"R Biundo","year":"2016","unstructured":"Biundo R, Weis L, Bostantjopoulou S, Stefanova E, Falup-Pecurariu C, Kramberger MG et al (2016) MMSE and MoCA in Parkinson\u2019s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm (Vienna) 123:431\u2013438","journal-title":"J Neural Transm (Vienna)"},{"key":"1653_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40120-022-00417-w","volume":"12","author":"J Chandler","year":"2023","unstructured":"Chandler J, Georgieva M, Desai U, Kirson N, Lane H, Cheung HC et al (2023) Disease progression and longitudinal clinical outcomes of Lewy body dementia in the NACC database. Neurol Ther 12:177\u2013195","journal-title":"Neurol Ther"},{"key":"1653_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant D-E, Farris CM, Ma Y, Urenia PA et al (2023) Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol 22:407\u2013417","journal-title":"Lancet Neurol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01653-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-023-01653-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01653-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T16:11:35Z","timestamp":1700323895000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-023-01653-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1653"],"URL":"https:\/\/doi.org\/10.1186\/s40478-023-01653-3","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"24 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of TUD (BO-EK-444092021), and written informed consent was obtained from all participants before inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SB, MR, JS, TH and PP report no competing interests. TG received speakers\u2019 honoraria by Lundbeck, UCB, and Desitin. He is member of advisory boards for Bayer, Eli Lilly and Ono Pharmaceuticals. KB reports grants from the German Research Foundation (DFG), German Parkinsons Disease Association (dPV), Michael J. Fox Foundation, outside the submitted work. She received travel grants from the Movement Disorders Society and speaker honoraria from Abbvie, Lundbeck, UCB and Zambon and was invited to Advisory Boards for F. Hoffmann La Roche Ltd. BF reports grants from the German Research Foundation (DFG) and speaker honoraria from AbbVie, Stadapharm, Desitin, Zambon and Bial.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}